drugset / Trial / NCT00140023

Azithromycin Microspheres in Patients With Low Risk Community Acquired Pneumonia

NCT00140023

Phase 3 Completed 47 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The study will assess the clinical efficacy at Day 14-21 (Test of Cure), 14-21 days after starting the study drug; those subjects from whom a baseline pathogen is identified will also be assessed for bacteriologic response. All subjects who receive 1 dose of study medication will be assessed for safety.

Timeline

Start
2005-09
Primary completion
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule

Indications